uracil mustard Report issue

Small molecule Approved FDA Priority Review FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Uramustine (INN) or uracil mustard is a chemotherapy drug which belongs to the class of alkylating agents. It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. Uracil Mustard selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Uracil Mustard-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. After activation, it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function. The DNA damage leads to apoptosis of the affected cells. Chemically it is a derivative of nitrogen mustard and uracil.   NCATS

Chemistry

  • SMILES: ClCCN(CCCl)C1=CNC(=O)NC1=O
  • InChIKey: IDPUKCWIGUEADI-UHFFFAOYSA-N
  • Mol. Mass: 252.098
  • ALogP: 0.35
  • ChEMBL Molecule:
    uracil mustard  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

5-aminouracil mustard | 5-[bis(2-chloroethyl)amino]-2,4(1h,3h)-pyrimidinedione | 5-(di-2-chloroethyl)aminouracil | 5-[di(beta-chloroethyl)amino]uracil | 5-n,n-bis(2-chloroethyl)aminouracil | aminouracil mustard | chlorethaminacil | demethyldopan | desmethyldopan | u-8344 | uracil mustard | uracil nitrogen mustard | uramustin | uramustine

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (3)


 

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Non-Hodgkin

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue